Industry Drug-Tracking Idea Not Worth The Cost, FDA Says

Law360, New York (April 18, 2012, 6:41 PM EDT) -- A top U.S. Food and Drug Administration official on Wednesday objected to an industry proposal to track and trace pharmaceuticals at the lot level, saying the plan would not solve major problems such as counterfeiting and therefore would not be worth the expense.

The proposal, known as the Pharmaceutical Traceability Enhancement Code, or RxTEC, has wide support from the pharmaceutical, generics and biologics industries, as well as from groups representing some pharmacists and drug distributors and from shipping company UPS Inc.

The proposal's wide support is...
To view the full article, register now.